Ciba Extends Isis Antisense Link-Up
Ciba and Isis Pharmaceuticals have announced the extension of their cooperative research and development agreement into antisense for a further three years, beginning in September 1995.
Ciba will continue to have worldwide exclusive marketing rights for compounds arising from the collaboration, which started in September 1990, with the exception of the USA where Ciba and Isis will comarket and copromote products arising from the arrangement. Isis will receive royalties on sales of products in other markets.
Isis has three antisense compounds in clinical trials: ISIS 2922 to treat CMV-induced retinitis in AIDS patients in Phase III; ISIS 2105 to treat genital warts caused by human papillomavirus as an adjunct to surgery in Phase II; and ISIS 2302, an ICAM-1 inhibitor, in Phase I trials for a number of inflammatory conditions. The company also has several preclinical programs ongoing, including ISIS 5320, a novel anti-HIV compound.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze